Lin281632 Options
Contraindicated (1)bortezomib will raise the degree or impact of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Robust or moderate CYP2C19 inhibitors might improve mavacamten systemic exposure, causing heart failure due to systolic dysfunction.Reduced ailment exercise has been described and examined, and by far the most